Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: Weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history

E. Jabbour, A. Hochhaus, J. Cortes, P. La Rosée, H. M. Kantarjian

Research output: Contribution to journalReview article

Abstract

For patients with chronic myeloid leukemia who become or are inherently resistant to imatinib therapy, including dose escalation, several important factors must be considered when deciding which strategy to attempt next. The second-generation tyrosine kinase inhibitors (TKIs) dasatinib and nilotinib offer improved potency and a high likelihood of success for these patients. Overall, the efficacy data are comparable for these two agents, and so physicians should consider the BCR-ABL mutation profile and the patient's history to make an educated decision on the best choice. Only a few BCR-ABL mutations seem to be less responsive to either nilotinib or dasatinib and it is recommended to choose the second-line TKI that has shown clinical activity against the specific mutation in these cases. For patients with all other mutations, and for patients with no mutations, it is recommended to choose the second-generation TKI based on the patient's disease history. It is important to choose an agent that minimizes the likelihood of exacerbating the patient's past tolerability issues to imatinib, or comorbid conditions. Here, we propose a treatment algorithm for imatinib-resistant patients based on BCR-ABL mutation status and patient history.

Original languageEnglish (US)
Pages (from-to)6-12
Number of pages7
JournalLeukemia
Volume24
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Safety
Mutation
Pharmaceutical Preparations
Protein-Tyrosine Kinases
Therapeutics
Imatinib Mesylate
Physicians

Keywords

  • BCR-ABL
  • Chronic myeloid leukemia
  • Dasatinib
  • Imatinib
  • Nilotinib
  • TKI

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib : Weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. / Jabbour, E.; Hochhaus, A.; Cortes, J.; La Rosée, P.; Kantarjian, H. M.

In: Leukemia, Vol. 24, No. 1, 01.2010, p. 6-12.

Research output: Contribution to journalReview article

@article{b66e158bb07d496e8402c195219b6aa2,
title = "Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: Weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history",
abstract = "For patients with chronic myeloid leukemia who become or are inherently resistant to imatinib therapy, including dose escalation, several important factors must be considered when deciding which strategy to attempt next. The second-generation tyrosine kinase inhibitors (TKIs) dasatinib and nilotinib offer improved potency and a high likelihood of success for these patients. Overall, the efficacy data are comparable for these two agents, and so physicians should consider the BCR-ABL mutation profile and the patient's history to make an educated decision on the best choice. Only a few BCR-ABL mutations seem to be less responsive to either nilotinib or dasatinib and it is recommended to choose the second-line TKI that has shown clinical activity against the specific mutation in these cases. For patients with all other mutations, and for patients with no mutations, it is recommended to choose the second-generation TKI based on the patient's disease history. It is important to choose an agent that minimizes the likelihood of exacerbating the patient's past tolerability issues to imatinib, or comorbid conditions. Here, we propose a treatment algorithm for imatinib-resistant patients based on BCR-ABL mutation status and patient history.",
keywords = "BCR-ABL, Chronic myeloid leukemia, Dasatinib, Imatinib, Nilotinib, TKI",
author = "E. Jabbour and A. Hochhaus and J. Cortes and {La Ros{\'e}e}, P. and Kantarjian, {H. M.}",
year = "2010",
month = "1",
doi = "10.1038/leu.2009.193",
language = "English (US)",
volume = "24",
pages = "6--12",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib

T2 - Weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history

AU - Jabbour, E.

AU - Hochhaus, A.

AU - Cortes, J.

AU - La Rosée, P.

AU - Kantarjian, H. M.

PY - 2010/1

Y1 - 2010/1

N2 - For patients with chronic myeloid leukemia who become or are inherently resistant to imatinib therapy, including dose escalation, several important factors must be considered when deciding which strategy to attempt next. The second-generation tyrosine kinase inhibitors (TKIs) dasatinib and nilotinib offer improved potency and a high likelihood of success for these patients. Overall, the efficacy data are comparable for these two agents, and so physicians should consider the BCR-ABL mutation profile and the patient's history to make an educated decision on the best choice. Only a few BCR-ABL mutations seem to be less responsive to either nilotinib or dasatinib and it is recommended to choose the second-line TKI that has shown clinical activity against the specific mutation in these cases. For patients with all other mutations, and for patients with no mutations, it is recommended to choose the second-generation TKI based on the patient's disease history. It is important to choose an agent that minimizes the likelihood of exacerbating the patient's past tolerability issues to imatinib, or comorbid conditions. Here, we propose a treatment algorithm for imatinib-resistant patients based on BCR-ABL mutation status and patient history.

AB - For patients with chronic myeloid leukemia who become or are inherently resistant to imatinib therapy, including dose escalation, several important factors must be considered when deciding which strategy to attempt next. The second-generation tyrosine kinase inhibitors (TKIs) dasatinib and nilotinib offer improved potency and a high likelihood of success for these patients. Overall, the efficacy data are comparable for these two agents, and so physicians should consider the BCR-ABL mutation profile and the patient's history to make an educated decision on the best choice. Only a few BCR-ABL mutations seem to be less responsive to either nilotinib or dasatinib and it is recommended to choose the second-line TKI that has shown clinical activity against the specific mutation in these cases. For patients with all other mutations, and for patients with no mutations, it is recommended to choose the second-generation TKI based on the patient's disease history. It is important to choose an agent that minimizes the likelihood of exacerbating the patient's past tolerability issues to imatinib, or comorbid conditions. Here, we propose a treatment algorithm for imatinib-resistant patients based on BCR-ABL mutation status and patient history.

KW - BCR-ABL

KW - Chronic myeloid leukemia

KW - Dasatinib

KW - Imatinib

KW - Nilotinib

KW - TKI

UR - http://www.scopus.com/inward/record.url?scp=74149095067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74149095067&partnerID=8YFLogxK

U2 - 10.1038/leu.2009.193

DO - 10.1038/leu.2009.193

M3 - Review article

C2 - 19798095

AN - SCOPUS:74149095067

VL - 24

SP - 6

EP - 12

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -